Mark Timney Speaks at the BIO CEO & Investor Conference

Mark Timney, CEO of Purdue Pharma L.P., participated in a BIO Buzz Center interview with Luke Timmerman about diversification opportunities during the 2016 BIO CEO & Investor Conference on February 8 in New York. (Watch the video interview embedded below.)

During the conference, Mark was a featured panelist for, “M&A in Overdrive: Deal-Making and Merger Integration Success Factors.” Stephen B. Thau, partner at Morrison & Foerster, served as the moderator. The other panelists included Henry Gosebruch, EVP and Chief Strategy Officer, AbbVie; Carol Gallagher, Partner, New Enterprise Associates; and James Sapirstein, CEO, ContraVir Pharmaceuticals. The conference, one of the largest investor conferences focused on biotech companies, provides a forum for institutional investors, industry analysts and senior biotechnology executives to meet.

The prescription and illicit opioid abuse crisis is a multifaceted public health challenge, and as a manufacturer of prescription opioids, we have a responsibility to join the fight. At Purdue we are committed to lead our industry in helping address our nation's prescription and illicit opioid abuse crisis.

There is more to come – as we continue to work with partners and experts to deliver solutions. Below you will find additional information about our efforts.

Read our open letter about the opioid crisis.